Melanotan II and Melanoma Risk
Melanotan and Melanocortins
Multiple case reports
Published case reports document melanoma developing in individuals using melanotan II, including melanoma in situ and invasive melanoma arising from existing moles during or shortly after use.
Hjuler et al., Dermatology, 2014
Hjuler et al., Dermatology, 2014
View as imageMelanotan II (MT-II) is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that activates melanocortin receptors, primarily MC1R, to stimulate melanin production and darken the skin without UV exposure. Developed in the 1990s at the University of Arizona as a potential skin cancer prevention agent, it was never approved by any regulatory agency for any indication. Instead, it spread through gray-market peptide suppliers as a tanning agent, often self-injected subcutaneously by users seeking darker skin.[1]
The irony is stark: a peptide originally designed to protect against skin cancer through increased melanin production has become the subject of multiple case reports linking it to melanoma, the deadliest form of skin cancer. Hjuler et al. (2014) published the most detailed case series in Dermatology, documenting melanoma developing in melanotan II users.[2] Ong and Bowling (2012) reported melanotan-associated melanoma in situ in the Australasian Journal of Dermatology.[3] Bohm et al. (2025) published the most comprehensive review of chronic melanocortin-1 receptor activation, weighing both benefits and risks in the context of approved MC1R drugs and unapproved analogs.[4]
This article examines the evidence linking melanotan II to melanoma risk, the underlying biology that makes this connection plausible, and what remains unknown. For the basic biology of how melanocortins control pigmentation, see The Melanocortin System and Skin Color: How Alpha-MSH Controls Pigment. For the differences between melanotan I and II, see Melanotan I vs Melanotan II: What They Are and Why They're Controversial. For the full side effect profile, see Melanotan II Side Effects: Nausea, Moles, and Cardiovascular Risks. For the only FDA-approved melanocortin, see Afamelanotide (Scenesse): The FDA-Approved Melanocortin for a Rare Disease.
Key Takeaways
- Multiple published case reports document melanoma (including melanoma in situ and invasive melanoma) arising in individuals using melanotan II, with tumors developing on existing moles within weeks to months of use (Hjuler et al., 2014; Ong and Bowling, 2012)
- Melanotan II activates MC1R on melanocytes, stimulating both melanin production and melanocyte proliferation; chronic activation of melanocyte growth pathways is a recognized risk factor for melanoma development
- Eruptive dysplastic (atypical) nevi have been reported in melanotan users, including in a teenager with familial atypical mole-melanoma syndrome (FAMMM), suggesting the peptide can trigger abnormal melanocyte growth in genetically susceptible individuals
- Bohm et al. (2025) reviewed the benefits and risks of chronic MC1R activation, noting that while MC1R signaling can protect DNA from UV damage, constitutive melanocyte stimulation carries theoretical oncogenic risk
- Nelson et al. (2012) documented systemic toxicity including rhabdomyolysis from melanotan II injection, highlighting that risks extend beyond melanoma to acute adverse events
- Melanotan II is not approved by the FDA, EMA, TGA, or MHRA for any indication; regulatory agencies in the US, UK, and Australia have issued warnings against its use
How melanotan II activates melanocytes
Melanotan II is a cyclic heptapeptide analog of alpha-MSH, the endogenous melanocortin hormone that controls skin pigmentation. The endogenous system works as follows: UV radiation damages keratinocyte DNA, triggering p53-dependent transcription of proopiomelanocortin (POMC). POMC is cleaved into alpha-MSH, which is secreted and binds MC1R on neighboring melanocytes. MC1R activation stimulates adenylate cyclase, raises intracellular cAMP, activates CREB transcription factor, and upregulates MITF (melanogenesis-associated transcription factor), which drives expression of tyrosinase and other melanin-synthesizing enzymes.[4]
This pathway is protective under normal conditions. Eumelanin (brown/black melanin) absorbs UV photons, scavenges free radicals, and physically shields melanocyte DNA from UV-induced damage. People with loss-of-function MC1R variants (common in red-haired, fair-skinned populations) produce predominantly pheomelanin (red/yellow melanin) instead, which is less photoprotective and may generate reactive oxygen species, contributing to the elevated melanoma risk in these populations.
Melanotan II bypasses the UV trigger entirely. It directly activates MC1R regardless of UV exposure, stimulating melanogenesis without the DNA damage signal that normally initiates the pathway. In theory, this could be protective: more melanin without the UV damage that usually precedes it. In practice, the concern is that chronic, non-physiological melanocyte stimulation could promote melanocyte proliferation and potentially malignant transformation.
A critical difference between melanotan II and the endogenous system is receptor selectivity. Alpha-MSH primarily activates MC1R, the receptor responsible for pigmentation. Melanotan II is a non-selective melanocortin agonist that activates MC1R through MC5R, producing effects on appetite (MC4R), sexual function (MC3R/MC4R), and other systems in addition to pigmentation. This non-selectivity means the peptide has pharmacological effects throughout the body, not just in the skin. Tomassi et al. (2022) developed CLIPS-constrained melanotan II analogs to achieve more selective MC receptor activation, demonstrating that the parent molecule's promiscuity across melanocortin receptors is recognized as a pharmacological liability.[1]
The dosing context also matters. Users typically self-administer melanotan II by subcutaneous injection, starting with a "loading phase" of daily injections followed by maintenance dosing once or twice weekly. The doses used are derived from online forums and user communities, not pharmacokinetic studies. There is no standardized potency, purity, or dosing for a product that has never undergone regulatory review. Contamination, mislabeling, and dosing errors are inherent risks of unregulated peptide markets.
The case reports: melanoma in melanotan users
Hjuler et al. (2014): melanoma associated with melanotan II
Hjuler et al. published the most cited case report linking melanotan II to melanoma in the journal Dermatology. They documented patients who developed melanoma while using or shortly after using melanotan II. In one case, a young woman developed melanoma on a pre-existing nevus (mole) within months of beginning melanotan II injections. The melanomas arose in typical anatomical locations and had histological features consistent with the usual melanoma subtypes, but the temporal association with melanotan II use was considered potentially significant.[2]
The authors noted that causality could not be established from case reports alone. Melanoma has a background incidence rate, and users of melanotan II tend to be people who also use tanning beds and seek UV exposure, both independent and well-established melanoma risk factors. Disentangling the melanotan II effect from the UV co-exposure is difficult, but the case reports raised sufficient concern to warrant dermatological attention.
Ong and Bowling (2012): melanoma in situ
Ong and Bowling reported a case of melanotan-associated melanoma in situ in the Australasian Journal of Dermatology. Melanoma in situ is the earliest stage, confined to the epidermis without invasion of the dermis. The case involved a melanotan user who developed the lesion on a pre-existing mole.[3]
Dysplastic nevi: eruptive atypical moles
Beyond melanoma, melanotan II has been linked to the development of dysplastic (atypical) nevi, moles with irregular borders, uneven pigmentation, and histological atypia. Dysplastic nevi are considered markers of melanoma risk: having more than 5 dysplastic nevi is an independent risk factor for melanoma, and some dysplastic nevi serve as precursors from which melanoma can develop.
One particularly concerning case involved a teenager with familial atypical mole-melanoma syndrome (FAMMM) who developed eruptive dysplastic nevi following melanotan injections combined with tanning bed use. FAMMM patients already carry germline CDKN2A mutations that predispose them to melanoma. The addition of a melanocyte-stimulating agent to this genetic background represents a potentially dangerous combination. CDKN2A encodes p16INK4a, a tumor suppressor that normally restrains melanocyte proliferation. When this brake is defective and melanocyte growth is simultaneously being stimulated by an exogenous MC1R agonist, the conditions for malignant transformation are theoretically optimized.
The pattern of mole changes reported in melanotan users is itself concerning from a dermatological perspective. Darkening of existing moles, development of new moles, and changes in mole morphology are the clinical warning signs dermatologists use to screen for melanoma (the ABCDE criteria: asymmetry, border irregularity, color variation, diameter, evolution). Melanotan II use induces exactly these changes across the entire skin, potentially masking genuine melanoma development among benign changes and making dermatological surveillance significantly more difficult.
The biological plausibility argument
The concern about melanotan II and melanoma is not based solely on case reports. There is a biological rationale for why chronic MC1R stimulation could promote melanoma.
Melanocyte proliferation
MC1R signaling does not only increase melanin production. It also affects melanocyte survival and proliferation. The cAMP-CREB-MITF pathway activated by MC1R promotes melanocyte proliferation and inhibits melanocyte apoptosis. Under normal conditions, this is tightly regulated: alpha-MSH is produced locally in response to UV damage, acts for a limited duration, and is then degraded. Melanotan II provides sustained, supraphysiological MC1R stimulation without the regulatory feedback mechanisms that control endogenous alpha-MSH levels.
The paradox of MC1R and melanoma
There is a genuine paradox in MC1R biology. Loss-of-function MC1R variants are associated with increased melanoma risk (through reduced eumelanin production and impaired DNA repair). This would seem to suggest that MC1R activation is protective. And in many respects it is: MC1R signaling enhances nucleotide excision repair of UV-induced DNA damage, independent of its effects on melanin production.
Bohm et al. (2025) addressed this paradox directly, noting that the protective effects of MC1R activation (enhanced DNA repair, increased eumelanin, free radical scavenging) must be weighed against the potential risks of chronic melanocyte stimulation (increased proliferation, inhibited apoptosis, promotion of melanocyte survival in conditions where damaged cells should undergo programmed cell death).[4]
The key variable may be duration and dosing. Physiological MC1R activation is transient, local, and UV-dependent. Pharmacological MC1R activation with melanotan II is chronic, systemic, and UV-independent. Whether this difference crosses the line from protective to oncogenic is the unresolved question. The regulatory landscape for unapproved peptides means this question may never be answered by randomized controlled trials.
The BRAF mutation question
The most common driver mutation in melanoma is BRAF V600E, found in approximately 50% of melanomas. BRAF V600E constitutively activates the MAPK/ERK signaling cascade, driving uncontrolled melanocyte proliferation. MC1R signaling intersects with this pathway: cAMP generated by MC1R activation can modulate ERK signaling through both stimulatory and inhibitory mechanisms depending on context.
In normal melanocytes, MC1R activation may actually suppress ERK-driven proliferation through cAMP-dependent mechanisms. But in melanocytes that have already acquired a BRAF V600E mutation (or other MAPK pathway mutations), the interaction between MC1R signaling and the constitutively active MAPK cascade may be different, potentially additive rather than inhibitory. Whether melanotan II could accelerate the progression of melanocytes that have already accumulated early mutations (as happens in dysplastic nevi) by providing an additional growth stimulus through MC1R is an open question that has not been directly tested.
This is the scenario that concerns dermatologists most: not that melanotan II initiates melanoma de novo, but that it may accelerate the progression of pre-malignant melanocytic lesions (dysplastic nevi, melanocytes with early mutations) toward frank melanoma. The case reports of melanoma arising from pre-existing moles in melanotan II users are consistent with this progression model rather than a de novo initiation model.
Systemic toxicity beyond melanoma
The safety concerns with melanotan II extend well beyond melanoma risk. Nelson et al. (2012) reported a case of systemic toxicity with rhabdomyolysis (destruction of muscle tissue) following melanotan II injection. The patient developed muscle pain, dark urine, and markedly elevated creatine kinase, requiring hospitalization.[5]
Other documented adverse effects include nausea (the most common side effect, occurring in a majority of users), facial flushing, spontaneous erections in males, changes in existing moles (darkening, growth, altered morphology), fatigue, and headache. The nausea is often severe enough that users take antiemetics before injection, a practice that normalizes pharmaceutical intervention to tolerate the side effects of an unapproved peptide.
Mestria et al. (2021) characterized the LC-HRMS profiles of melanotan II and bremelanotide in biological samples, contributing to the analytical chemistry needed for clinical toxicology and forensic identification of these peptides.[6] This analytical work is important because emergency departments and poison control centers increasingly encounter melanotan II-related presentations, and the ability to confirm exposure through laboratory analysis supports clinical decision-making. Gao et al. (2015) characterized a novel melanotan II analog with superpotent melanotropic activity, demonstrating that the peptide chemistry landscape continues to generate increasingly potent MC receptor agonists that may enter the unregulated market.[7]
The full range of melanotan II side effects includes cardiovascular risks, gastrointestinal effects, and the cosmetic issue of permanently altered moles.
UV co-exposure: the compounding risk factor
The majority of melanotan II users do not use the peptide in isolation. They combine it with UV exposure, either from tanning beds or natural sunlight, because the melanocyte stimulation from the peptide works synergistically with UV to produce deeper, faster tanning. This combination is concerning for two independent reasons.
First, UV radiation is the single strongest environmental risk factor for melanoma. Tanning bed use before age 35 increases melanoma risk by 59% (meta-analysis data). Melanotan II users who are motivated enough to inject a tanning peptide are frequently the same people who use tanning beds, creating a population that is simultaneously exposed to a DNA-damaging agent (UV) and a melanocyte-stimulating agent (melanotan II). This combination provides both the mutagenic trigger (UV-induced DNA damage) and the growth signal (MC1R-driven melanocyte proliferation) that are the two fundamental requirements for melanoma development.
Second, the melanin produced in response to melanotan II may not be functionally equivalent to UV-induced melanin in terms of photoprotection. Endogenous melanogenesis in response to UV is a coordinated process: melanin is produced, packaged into melanosomes, and transferred to surrounding keratinocytes where it forms supranuclear caps that shield DNA from further UV damage. Whether melanotan II-induced melanin undergoes the same orderly packaging and distribution, or whether it is produced in a less organized fashion that provides less effective photoprotection, has not been rigorously studied. If melanotan II produces melanin that looks like a tan but does not protect like a tan, users who rely on their artificially dark skin as UV protection could be accumulating DNA damage at rates closer to their untanned baseline.
This point is important because a common justification among melanotan II users is that the peptide protects them from sun damage by increasing melanin. If this protection is incomplete or illusory, the cosmetic appearance of a deep tan could create a false sense of security that leads to greater UV exposure than the individual would otherwise seek, further compounding melanoma risk.
What the evidence does and does not show
The evidence linking melanotan II to melanoma consists of case reports and biological plausibility. No epidemiological study has quantified the relative risk. No controlled trial has compared melanoma rates between users and non-users. The case reports are confounded by co-exposure to UV radiation (tanning beds), which is itself a strong melanoma risk factor.
The strongest evidence comes from the dysplastic nevi observations. The development of new atypical moles in melanotan users, particularly the eruptive dysplastic nevi in a genetically predisposed teenager, demonstrates that the peptide can induce abnormal melanocyte growth in living humans. Dysplastic nevi are established melanoma precursors. The induction of these lesions provides direct evidence that melanotan II promotes the kind of melanocytic dysplasia that is on the biological continuum toward melanoma.
The weakest evidence is the melanoma case reports themselves. Melanoma has a lifetime risk of approximately 1 in 38 in the United States. People who use melanotan II tend to be young adults who also use tanning beds and seek UV exposure. It is impossible to determine from case reports alone whether the melanoma would have occurred regardless of melanotan II use.
There is also a significant absence of evidence. Afamelanotide (Scenesse), an FDA-approved MC1R agonist based on alpha-MSH (not melanotan II), has been used for erythropoietic protoporphyria since 2019. Its long-term safety monitoring has not identified a melanoma signal in the treated population, though the number of patients is small and follow-up is relatively short. Whether the favorable safety profile of afamelanotide (which is MC1R-selective) can be extrapolated to melanotan II (which is non-selective across melanocortin receptors and is used at uncontrolled doses from unregulated sources) is uncertain. For more on the approved drug, see Afamelanotide (Scenesse): The FDA-Approved Melanocortin for a Rare Disease.
The safety monitoring gaps for compounded peptides are particularly relevant here. Without regulatory oversight, there is no pharmacovigilance system tracking adverse events in melanotan II users. Case reports reach the literature only when a clinician recognizes the association and chooses to publish. The true incidence of melanoma or dysplastic nevi in melanotan II users is unknown, and may remain unknown unless prospective cohort studies are conducted, which is unlikely for an unapproved substance.
The regulatory position
Melanotan II is not approved for any indication by the FDA (United States), EMA (European Union), TGA (Australia), or MHRA (United Kingdom). All four agencies have issued explicit warnings against its use.
The Australian TGA has been particularly vocal, issuing multiple consumer alerts and confiscating melanotan II products at the border. The UK MHRA has warned that melanotan products are illegal to sell and "could cause serious harm." The FDA has not approved melanotan II as a drug and considers its sale for human use a violation of the Federal Food, Drug, and Cosmetic Act.
Despite these warnings, melanotan II remains widely available through online peptide vendors, typically sold as a "research chemical" not for human consumption. The legal fiction of the "research use only" label is well-documented in the peptide marketplace.
Social media has amplified melanotan II's reach, particularly through TikTok and Instagram where "nasal tanning sprays" (a newer delivery form) gained viral popularity in 2023-2024. These products repackage the same MC1R agonist in a form that avoids injection, lowering the barrier to use. The marketing typically emphasizes the cosmetic tanning effect without mentioning the melanoma risk, the regulatory status, or the adverse effect profile.
The contrast with afamelanotide is instructive. Afamelanotide went through a full regulatory approval process, including long-term safety monitoring, controlled manufacturing, and post-market surveillance. It is prescribed by specialists for a specific rare disease (erythropoietic protoporphyria) and administered as a subcutaneous implant every two months. Melanotan II has none of these safeguards. It is self-administered at self-determined doses from unregulated sources. The population using it is orders of magnitude larger than the afamelanotide patient population, yet there is no safety monitoring infrastructure. This represents one of the most significant examples of the gap between regulated and unregulated peptide therapeutics.
The Bottom Line
Melanotan II is an unapproved MC1R agonist used illicitly for skin tanning. Multiple case reports document melanoma and dysplastic nevi in users, and the biological mechanism connecting chronic melanocyte stimulation to malignant transformation is well-characterized. The evidence is strongest for the induction of atypical moles (dysplastic nevi), which are established melanoma precursors. The evidence for direct melanoma causation is limited to case reports confounded by UV co-exposure. No regulatory agency approves melanotan II for any use, and the absence of pharmacovigilance data means the true risk magnitude is unknown.